COMMUNIQUÉS West-GlobeNewswire

COVID mRNA Vaccines May Alter Gene Expression, according to Journal of American Physicians and Surgeons
09/03/2026
TUSCON, Ariz., March 09, 2026 (GLOBE NEWSWIRE) -- The mechanism of action of mRNA vaccines goes far beyond harnessing host cellular machinery to produce antigenic proteins to spur immunity, write Nicolas Hulscher , M.P. [...]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
09/03/2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution [...]
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
09/03/2026
HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Sherry Cummings, Chief Executive Officer of Gryphon Healthcare , has been named one of the 2026 Women to KNOW in Texas , a prestigious statewide honor recognizing women who [...]
Slim Force BHB Ketone Claims Evaluated: 2026 Consumer Research Report on SlimForce Ingredients, Ketogenic Supplement Positioning, and What Adults Should Verify Before Purchasing
09/03/2026
An informational 2026 consumer research report examining Slim Force exogenous ketone formulation, BHB salt research context, proprietary blend transparency, pricing disclosures, and verification considerations for [...]
Xenon Pharmaceuticals Announces Proposed Public Offering
09/03/2026
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
09/03/2026
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class [...]
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
09/03/2026
– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
09/03/2026
Please see enclosed pdf. Attachment 09032026_trading_in_shares_NBC
Kristen Boehmer of Empowered Lyfe Partners with MD Logic Health to Launch Daily Colostrum, an Advanced Low Molecular Weight Bioactive Colostrum
09/03/2026
Miami, FL, March 09, 2026 (GLOBE NEWSWIRE) -- As consumer awareness surrounding the connection between gut health and overall wellness continues to rise, demand for simple, high-quality, science-backed solutions is [...]
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]
VisiFlora Gut-Eye Vision Support Claims Examined: 2026 Consumer Report on the 22-Ingredient Formula, Gut-Eye Axis Research, and What Adults Researching Vision Supplements Should Verify
09/03/2026
A 2026 informational consumer research report examining VisiFlora's gut-eye axis positioning, ingredient research context, 22-ingredient formula structure, pricing disclosures, and independent verification [...]
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
09/03/2026
PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik ® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les indications. La [...]
The Great Give Back brings community together in support of Royal Columbian Hospital
09/03/2026
NEW WESTMINSTER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation is inviting the community to come together for The Great Give Back, presented by Pan American Silver , a free, [...]
FocusMax Cognitive Support Claims Evaluated: Latest 2026 Consumer Research Report on FocusMax Ingredients, Proprietary Blend Dosing, and Cognitive Supplement Research
09/03/2026
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verification [...]
Choice Healthcare Services Announces Expansion of Children’s Choice Pediatric Dentistry Locations in California
09/03/2026
Two Locations to Launch New, Enhanced Offices in 2026 for Greater Patient Comfort and Accessibility Sacramento, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Choice Healthcare Services , the parent company of Children’s Choice [...]
MemoTril Consumer Concerns Under Investigation: Critiquing The Memo Tril Claims
09/03/2026
A 2026 consumer research report examining MemoTril marketing claims, ingredient transparency, refund policies, manufacturing disclosures, and verification considerations for adults researching cognitive support [...]
Transactions in Connection with Share Buy-back Program
09/03/2026
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
Zealand Pharma to participate in upcoming investor conferences in March 2026
09/03/2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, [...]

Pages